RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 3

Registered title, quoted from ClinicalTrials.gov

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07355283, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed CD20-positive Follicular Lymphoma, Grade 1, 2, or 3a.

    Inclusion criterion 3

  3. Previously received at least two prior systemic regimens, including at least one line containing an anti-CD20 monoclonal antibody.

    Inclusion criterion 4

    Autologous HSCT within 100 days prior to first administration, or any prior allogeneic HSCT or solid organ transplantation.

    Exclusion criterion 1

    Previous treatment with anti-CD47 monoclonal antibody/SIRPα fusion protein.

    Exclusion criterion 6

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 1

  5. At least one measurable lesion (as per Lugano 2014 criteria).

    Inclusion criterion 2

  6. History of other malignancy within the past 5 years.

    Exclusion criterion 3

    Human immunodeficiency virus (HIV) infection.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07355283, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • At least one measurable lesion (as per Lugano 2014 criteria).
  • Histologically confirmed CD20-positive Follicular Lymphoma, Grade 1, 2, or 3a.
  • Previously received at least two prior systemic regimens, including at least one line containing an anti-CD20 monoclonal antibody.
  • Adequate hepatic, hematologic, and renal function.
  • Expected survival at least 6 months.

Exclusion Criteria:

  • Autologous HSCT within 100 days prior to first administration, or any prior allogeneic HSCT or solid organ transplantation.
  • History of central nervous system (CNS) metastases or active CNS involvement.
  • History of other malignancy within the past 5 years.
  • Severe organic cardiovascular or cerebrovascular diseases.
  • History of severe allergic reactions to any components of the trial drug, any macromolecular protein preparations or monoclonal antibodies.
  • Previous treatment with anti-CD47 monoclonal antibody/SIRPα fusion protein.
  • Human immunodeficiency virus (HIV) infection.
  • Echocardiography examination indicating left ventricular ejection fraction (LVEF) < 55%.
  • Active infection requiring systemic therapy (e.g., fungal, bacterial, viral).

Quoted from ClinicalTrials.gov, NCT07355283, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07355283, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07355283